Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis

Figure 4

Forest plot of risk ratio of reduction of prostate-specific antigen ≥50% of sipuleucel-T and androgen receptor-directed therapies compared with placebo in men with castration-resistant prostate cancer. The bars with squares in the middle represent 95% confidence intervals (95% CIs) and RRs. The central vertical solid line indicates the RRs for null hypothesis. The size of the diamonds represents the weight for the random-effect model in the meta-analysis.